{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"175-545-362-583-781","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"175-545-362-583-781"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8837,"type":"PATENT","title":"University of Minnesota Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8933,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8208,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicant and Owners respectively = \"Univ Minnesota\" , \" Minnesota Univ\", \" University of Minnesota\", \"Minnesota University\", \"Univ Minne*\" , \" Minne* Univ*.
Select more for logical variants
Add to collection
Select all patents in the collection and expand by simple families.
Add to collection
Total patents: 7910
Search Applicant and Owners respectively = \"Univ Minnesota\" , \" Minnesota Univ\", \" University of Minnesota\", \"Minnesota University\", \"Univ Minne*\" , \" Minne* Univ*.
Select more for logical variants
Add to collection
Select all patents in the collection and expand by simple families.
Add to collection
Total patents: 7910
a first amino acid sequence;\n
a second amino acid sequence; and\n
a β-turn inducing scaffold bonded between the first and second amino acid sequences;\n
wherein the first amino acid sequence consists of an amino acid sequence selected from the group consisting of ANIKLSVQMKL (SEQ ID NO:8) and a segment of SEQ ID NO:8;\n
wherein the second amino acid sequence consists of an amino acid sequence selected from the group consisting of IIVKLND (SEQ ID NO:2) and a segment of SEQ ID NO;2;\n
wherein a segment of SEQ ID NO:8 consists of at least three contiguous amino acids of SEQ ID NO:8;\n
wherein a segment of SEQ ID NO:2 consists of at least one contiguous amino acid of SEQ ID NO:2; and\n
wherein segment provides the partial peptide mimetic with at least one of the following activities: inhibition of endothelial cell proliferation in vitro at an IC50 level of less than 80 mM; inhibition of angiogenesis in vitro at a level of less than 85% sprouting in a collagen gel-based assay; or reduction in tumor volume in vivo by at least 25% relative to a control at the end of an administration period."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The partial peptide mimetic of claim 2 wherein the first amino acid sequence consists of a segment of SEQ ID NO:8, from which a deletion has been made at the N-terminus of SEQ ID NO:8 by 1, 2, 3, 4, 5, 6, 7, or 8 residues."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The partial peptide mimetic of claim 2 wherein the first amino acid sequence consists of an amino acid selected from the group consisting of MKL, QMKL (SEQ ID NO:4), SVQMKL (SEQ ID NO:5), IKLSVQMKL (SEQ ID NO:6), NIKLSVQMKL (SEQ ID NO:7), and ANIKLSVQMKL (SEQ ID NO:8)."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The partial peptide mimetic of claim 2 wherein the first amino acid sequence is ANIKLSVQMKL (SEQ ID NO:8) and the second amino acid sequence is IIVKLND (SEQ ID NO:2)."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The partial peptide mimetic of claim 1 wherein the second amino acid sequence consists of a segment of SEQ ID NO:2 from which a deletion has been made at the C-terminus of SEQ ID NO:2 by 1, 2, 3, 4, 5, or 6 residues."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The partial peptide mimetic of claim 1 wherein the second amino acid sequence consists of an amino acid sequence selected from the group consisting of I, IIVK (SEQ ID NO:3), IIVKLN (SEQ ID NO:9) and IIVKLND (SEQ ID NO:2)."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The partial peptide mimetic of claim 7 wherein the first amino acid sequence consists of an amino acid sequence selected from the group consisting of MKL, QMKL (SEQ ID NO:4), SVQMKL (SEQ ID NO:5), IKLSVQMKL (SEQ ID NO:6), NIKLSVQMKL (SEQ ID NO:7), and ANIKLSVQMKL (SEQ ID NO:8)."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The partial peptide mimetic of claim 1 wherein the β-turn inducing scaffold is a dibenzofuran-containing scaffold."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The partial peptide mimetic of claim 1, wherein the partial peptide mimetic has at least one of the following activities: inhibition of endothelial cell proliferation in vitro at an IC50 level of less than 80 μM; inhibition of angiogenesis in vitro at a level of less than 85% sprouting in a collagen gel-based assay; or reduction in tumor volume in vivo by at least 25% relative to a control at the end of an administration period."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A partial peptide mimetic selected from the group consisting of:\n
ANIKLSVQMK (SEQ ID NO:8) and IIVKLND (SEQ ID NO:2), with a β-turn inducing scaffold bonded therebetween;\n
NIKLSVQMKL (SEQ ID NO:7) and IIVKLND (SEQ ID NO:2), with a β-turn inducing scaffold bonded therebetween;\n
JKLSVQMKL (SEQ ID NO:6) and IIVKLND (SEQ ID NO:2), with a β-turn inducing scaffold bonded therebetween;\n
SVQMKL (SEQ ID NO:5) and IIVKLND (SEQ ID NO:2), with a β-turn inducing scaffold bonded therebetween;\n
QMKL (SEQ ID NO:4) and IIVKLND (SEQ ID NO:2), with a β-turn inducing scaffold banded therebetween;\n
MKL and IIVKLND (SEQ ID NO:2), with a β-turn inducing scaffold bonded therebetween;\n
L and IIVKLND (SEQ ID NO:2), with a β-turn inducing scaffold bonded therebetween;\n
ANIKLSVQMKL (SEQ ID NO:8) and IIVKLN (SEQ ID NO:9), with a β-turn inducing scaffold bonded therebetween;\n
ANIKLSVQMKL (SEQ ID NO:8) and IIVK (SEQ ID NO:3), with a β-turn inducing scaffold bonded therebetween;\n
ANIKLSVQMK (SEQ ID NO:8) and I, with a β-turn inducing scaffold bonded therebetween;\n
SVQMKL (SEQ ID NO:5) and IIVK (SEQ ID NO:9), with a β-turn inducing scaffold bonded therebetween;\n
SVQMKL (SEQ ID NO:5) and IIVK (SEQ ID NO:3), with a β-turn inducing scaffold bonded therebetween;\n
SVQMKL (SEQ ID NO:5) and IIV, with a β-turn inducing scaffold bonded therebetween;\n
SVQMKL (SEQ ID NO:5) and II, with a β-turn inducing scaffold bonded therebetween; and\n
SVQMKL (SEQ ID NO:5) and I, with a β-turn inducing scaffold bonded therebetween."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The partial peptide mimetic of claim 11 wherein the partial peptide mimetic has at least one of the following activities: inhibition of endothelial cell proliferation in vitro at an IC50 level of less than 80 μM; inhibition of angiogenesis in vitro at a level of less than 85% sprouting in a collagen gel-based assay; or reduction in tumor volume in vivo by at least 25% relative to a control at the end of an administration period."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["A method far inhibiting endothelial cell proliferation, the method comprising contacting cells with an amount of a composition effective to inhibit endothelial cell proliferation, wherein the composition comprises a partial peptide mimetic of any one of claims 1, 2, 11."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13 wherein the contacting step occurs in vitro."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13 wherein the contacting step occurs in vivo."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13 wherein the cells are present in a cell culture, a tissue, an organ, or an organism."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13 wherein the cells arc mammalian cells."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13 wherein the cells are human cells."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["A method for inhibiting angiogenesis, the method comprising contacting cells with an amount of a composition effective to inhibit angiogenesis, the composition comprising a partial peptide mimietic of any one of claims 1, 2, 11."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19 wherein the contacting step occurs in vitro."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19 wherein the contacting step occurs in vivo."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19 wherein the cells are present in a cell culture, a tissue, an organ, or an organism."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19 wherein the cells are mammalian cells."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19 wherein the cells are human cells."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["A method for inhibiting tumorigenesis in a patient, the method comprising administering to the patient a therapeutically effective amount of a composition comprising a partial peptide mimetic of any one of claims 1, 2, 11."],"number":25,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}